logo-loader
viewInvitrocue Ltd

Invitrocue launches personalised cancer screening service in Singapore

Enabling oncologists to develop better informed and more personalised treatment strategies for patients.

cancer screening service
The world’s first commercial personalised cancer screening service

Invitrocue (ASX:IVQ) has screened the first commercial Onco-PDO customer in Singapore for the indication of colorectal cancer.

The company’s Onco-PDO test provides an overview of how a patient’s cancer cells respond to different chemotherapies, ranking these therapeutics based on their effectiveness in delivering a positive response.

Importantly, this approach allows oncologists to develop better informed and more personalised treatment strategies for patients.

Positive response from oncologists

Screening the PDO models for the first paying customer signals the initial commercial applications of Invitrocue’s technology and approach in the Asia Pacific region.

Invitrocue chief executive Dr Steven Fang said: “We are incredibly excited to have screened our first patient in Singapore against the OncoPDO drug sensitivity test, and are encouraged by the response and interest so far from both local and international oncologists in using this technology with their patients to better inform their decision-making process when dealing with a variety of cancer types.”

More patients identified to use the test

Invitrocue has identified key medical channel partners for Singapore and will also be receiving patients from Hong Kong who are looking to utilise the Onco-PDO platform.

All clinical work to offer Onco-PDO services is being carried out at the joint laboratory established last year between the Genome Institute of Singapore (GIS) and Invitrocue.

READ: Invitrocue and Genome Institute of Singapore to develop in vitro cancer models

The laboratory is located at A*STAR, the Singapore government’s Agency for Science, Technology and Research.

Quick facts: Invitrocue Ltd

Price: 0.06 AUD

ASX:IVQ
Market: ASX
Market Cap: $31.52 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Invitrocue leads market with disruptive technology and personalised oncology...

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours.    "We've been able to take some of these really...

on 20/5/19

2 min read